Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

医学 耐受性 内科学 间质性肺病 类风湿性关节炎 吡非尼酮 安慰剂 双盲 关节炎 不利影响 特发性肺纤维化 病理 替代医学
作者
Joshua J. Solomon,Sonye K. Danoff,Felix Woodhead,Shelley Hurwitz,Rie Maurer,Ian Glaspole,Paul F. Dellaripa,Bibek Gooptu,Robert Vassallo,Gerard Cox,Kevin R. Flaherty,Huzaifa Adamali,Michael Gibbons,Lauren Troy,Ian Forrest,Joseph A. Lasky,Lisa Spencer,Jeffrey A. Golden,Mary Beth Scholand,Nazia Chaudhuri
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:11 (1): 87-96 被引量:133
标识
DOI:10.1016/s2213-2600(22)00260-0
摘要

Summary

Background

Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Methods

TRAIL1 was a randomised, double-blind, placebo-controlled, phase 2 trial done in 34 academic centres specialising in interstitial lung disease in four countries (the UK, the USA, Australia, and Canada). Adults aged 18–85 years were eligible for inclusion if they met the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology criteria for rheumatoid arthritis and had interstitial lung disease on a high-resolution CT scan imaging and, when available, lung biopsy. Exclusion criteria include smoking, clinical history of other known causes of interstitial lung disease, and coexistant clinically significant COPD or asthma. Patients were randomly assigned (1:1) to receive 2403 mg oral pirfenidone (pirfenidone group) or placebo (placebo group) daily. The primary endpoint was the incidence of the composite endpoint of a decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or more or death during the 52-week treatment period assessed in the intention-to-treat population. Key secondary endpoints included change in absolute and FVC% over 52 weeks, the proportion of patients with a decline in FVC% of 10% or more, and the frequency of progression as defined by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02808871.

Findings

From May 15, 2017, to March 31, 2020, 231 patients were assessed for inclusion, of whom 123 patients were randomly assigned (63 [51%] to the pirfenidone group and 60 [49%] to the placebo group). The trial was stopped early (March 31, 2020) due to slow recruitment and the COVID-19 pandemic. The difference in the proportion of patients who met the composite primary endpoint (decline in FVC% from baseline of 10% or more or death) between the two groups was not significant (seven [11%] of 63 patients in the pirfenidone group vs nine [15%] of 60 patients in the placebo group; OR 0·67 [95% CI 0·22 to 2·03]; p=0·48). Compared with the placebo group, patients in the pirfenidone group had a slower rate of decline in lung function, measured by estimated annual change in absolute FVC (–66 vs –146; p=0·0082) and FVC% (–1·02 vs –3·21; p=0·0028). The groups were similar with regards to the decline in FVC% by 10% or more (five [8%] participants in the pirfenidone group vs seven [12%] in the placebo group; OR 0·52 [95% CI 0·14–1·90]; p=0·32) and the frequency of progression as defined by OMERACT (16 [25%] in the pirfenidone group vs 19 [32%] in the placebo group; OR 0·68 [0·30–1·54]; p=0·35). There was no significant difference in the rate of treatment-emergent serious adverse events between the two groups, and there were no treatment-related deaths.

Interpretation

Due to early termination of the study and underpowering, the results should be interpreted with caution. Despite not meeting the composite primary endpoint, pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials.

Funding

Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
粥可温完成签到,获得积分10
刚刚
曾珍发布了新的文献求助10
1秒前
2秒前
hzh完成签到 ,获得积分10
3秒前
gg发布了新的文献求助10
3秒前
勤劳滑板完成签到 ,获得积分10
3秒前
Jerry完成签到,获得积分10
4秒前
MrLiu完成签到,获得积分10
5秒前
冷傲博完成签到,获得积分10
5秒前
jeff完成签到,获得积分10
5秒前
LHZ完成签到,获得积分10
5秒前
所所应助时尚俊驰采纳,获得10
6秒前
影子芳香完成签到 ,获得积分10
7秒前
8秒前
8秒前
不必要再讨论适合与否完成签到,获得积分0
9秒前
无情夏寒完成签到 ,获得积分10
10秒前
慕青应助马士全采纳,获得10
11秒前
xuzj应助科研通管家采纳,获得10
11秒前
Rubby应助科研通管家采纳,获得30
12秒前
SciGPT应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
shiizii应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
12秒前
ludong_0应助科研通管家采纳,获得10
12秒前
YeeYee发布了新的文献求助10
12秒前
冷酷的松思完成签到,获得积分10
12秒前
zgt01发布了新的文献求助10
13秒前
zhang完成签到,获得积分10
13秒前
江中完成签到 ,获得积分10
15秒前
15秒前
阿玖完成签到 ,获得积分10
16秒前
jiaolulu发布了新的文献求助10
18秒前
踏雪飞鸿完成签到,获得积分10
19秒前
hannah完成签到,获得积分10
19秒前
songvv发布了新的文献求助10
20秒前
一一一应助Bin_Liu采纳,获得10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022